EGFR and breast carcinoma: MEDICA treatment is shown here to suppress ErbB2 breast cancer in vivo and cell lines by targeting mitochondrial oxidative phosphorylation, resulting in suppression of ErbB family members and inhibition of mTORC1 activity.